Volastra Therapeutics, a NYC-based biotechnology company developing novel therapies for the treatment of metastatic cancers, raised $12m in funding.
The company intends to use the funds to develop therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis.
Lewis Cantley, Samuel Bakhoum, and Olivier Elemento, Volastra is a biotechnology company focused on developing novel therapies for patients with metastatic cancers by exploiting unique insights into chromosomal instability.
Volastra Therapeutics’ operations are located at Johnson & Johnson Innovation, JLABS at New York City (JLABS @ NYC).
Following the deal, Executive Chair Sandra Peterson, a Partner at Clayton, Dubilier, and Rice, a Board Member of Microsoft, and the former Group Worldwide Chairman of Johnson & Johnson, will lead the Volastra Board of Directors. | To read full story, visit https://startuparound.com/read/1581460210.3841195/Volastra-Therapeutics-Raises-$12M-in-Seed-Financing?ref=audio_experience